Lv1
33 积分 2020-10-23 加入
A PHASE IB, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED MOSUNETUZUMAB IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
5小时前
求助中
POS1160 A PHASE IB, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED MOSUNETUZUMAB IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
5小时前
已完结
Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression Results From 2 Randomized, Double-Blind Studies
2个月前
已完结
Back to therapeutic modality basics
2个月前
已关闭
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
2个月前
已完结
Human circulating and tissue-resident memory CD8+ T cells
2个月前
已完结
Stem-like exhausted and memory CD8+ T cells in cancer
2个月前
已完结
A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells
2个月前
已完结
The diversity of CD8+ T cell dysfunction in cancer and viral infection
3个月前
已完结
Antibody drug conjugate combats inflammation
3个月前
已完结
皖公网安备34019202002308
